CollPlant Biotechnologies signs distribution agreement for its gel product


CollPlant Biotechnologies (CLGN) signs an agreement for distribution of its Vergenix Flowable Gel product in six CIS states: Belarus, Kazakhstan, Georgia, Azerbaijan, Armenia and Uzbekistan.

A Swiss-headquartered pharmaceutical group of companies has a five-year agreement for distribution.

Vergenix FG is based on company’s rhCollagen technology and is a wound-care product designed to treat acute and chronic hard-to-heal wounds.

Based on the deal, the company will deliver a portion of the order immediately and the remainder over the next six months.

“We are proud of the transformative potential of our recombinant human collagen platform technology that facilitates optimal treatment options for patients and remain open to additional collaborations that will bolster commercial infrastructure for Vergenix™ FG as well as support for our pipeline development efforts. At the same time, we continue to strategically focus on innovative applications of our rhCollagen in medical aesthetics and 3D Bioprinting of organs and tissues.” says CEO Yehiel Tal.





READ SOURCE

READ  Matt Hudson leaves Schroders after losing UK Opportunities fund

LEAVE A REPLY

Please enter your comment!
Please enter your name here